Using Imaging Data and Genomic Data to Predict Metastasis of Breast Cancer After Treatment

NCT03941639 | Terminated

• 1 other identifier: 2019.089
• Study Type: observational
• Target: 95
• Locations: 1 country
• Sites: 1

Brief Summary

Breast cancer is the second leading cause of death for women around the world. Notably, most breast cancer patients die from tumor metastases in the liver, lungs, bones, or brain, not the primary tumor itself. Currently, clinicians are generally successful in treating primary tumors using standard protocols that are based on tumor sub-type and staging, as well as by the presence or absence of prognostic biomarkers. However, it remains difficult to assess in advance the likelihood of metastasis or relapse in any given patient.Physicians can only rely on regular post-treatment screening to monitor any secondary onset. By the time metastasis is detected, the golden window for treatment adjustment has often already passed. This project proposes to develop an analytical tool for predicting the likelihood of metastasis in breast cancer patients post-treatment using imaging and genomic data. We will evaluate our prediction model using prospectively-collected patient data. This new prognostic tool will enable physicians to adjust and tailor therapeutic strategies to each patient in a timely manner. Overall, the tool will personalize patient care, and improve their survival chances and quality of life.

Conditions

Breast Cancer

Keywords

breast cancer; metastasis; prediction

Outcome Measures

Primary Outcomes (1)

• area under the receiver operating characteristic curve (AUC)

  AUC in percentage (%) in breast cancer metastasis prediction model

  Four years after patient recruitment

Eligibility Criteria

• Sex: female
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

BGI Ltd. will provide imaging data and genomic data from 200 breast cancer patients for us. Dr. Wing Cheong Chan is a breast surgeon at the North District Hospital (NDH) and is also the surgeon in charge of breast surgery for the Hospital Authority's entire New Territories East Cluster (NTEC). He will be responsible for recruiting 200 breast cancer patients. Prof. Winnie Yeo is a clinical oncologist at the Prince of Wales Hospital (PWH) of CUHK. She will be responsible for monitoring the 200 breast cancer patients, and will collect blood samples during the follow-up period.

You may qualify if:

• Clinical diagnosis of breast cancer
• With mammogram
• With surgical treatment
• With chemotherapy, radiotherapy or both

You may not qualify if:

• Clinical diagnosis of other major diseases

Sponsors & Collaborators

• Chinese University of Hong Kong: lead
• Department of Electronic and computer engineering, HKUST: collaborator
• Department of clinical oncology, CUHK: collaborator
• Department of Anatomical and Cellular Pathology,PWH: collaborator
• Department of Surgery, North District Hospital: collaborator

Study Sites (1)

The Chinese University of Hong Kong, Prince of Wale Hospital

Hong Kong, Shatin, Hong Kong

Location

Biospecimen

Retention: SAMPLES WITH DNA

This proposed project will include one retrospective study and one prospective pilot study. In retrospective study, the BGI Ltd, which company is sponsoring this project, will provide imaging data and genomic data from 200 breast cancer patients for us. In prospective study, we will recruit 200 breast cancer patients and acquire tumor tissue and blood samples for genomic data acquisition.

MeSH Terms

Conditions

Breast Neoplasms; Neoplasm Metastasis

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Weichuan Yu, Ph.D

  Department of Electronic and computer engineering, HKUST

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: OTHER
• Target Duration: 4 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: April 25, 2019
• First Posted: May 8, 2019
• Study Start: September 1, 2019
• Primary Completion: September 30, 2022
• Study Completion: December 31, 2022
• Last Updated: February 13, 2025

Record last verified: 2025-02

Data Sharing

• IPD Sharing: Will not share

Locations

HK (1)